From: Evaluation of pretreatment ADC values as predictors of treatment response to neoadjuvant chemotherapy in patients with breast cancer - a multicenter study
Overall patient sample
Luminal A
Luminal B
HER2-enriched
Triple negative
ADC-values (10− 3 mm2/s, M ± SD
1.04 ± 0.24
1.05 ± 0.18
0.93 ± 0.21
1.07 ± 0.22
1.10 ± 0.29